{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Minneapolis&page=43&state=Minnesota",
    "query": {
      "state": "Minnesota",
      "city": "Minneapolis",
      "page": 43
    },
    "page_size": 10
  },
  "pagination": {
    "page": 43,
    "page_size": 10,
    "total_count": 7881,
    "total_pages": 789,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Minneapolis&page=44&state=Minnesota&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Minneapolis&page=42&state=Minnesota&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T19:40:57.791Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02715804",
      "title": "A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pancreatic Ductal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20)",
          "type": "OTHER"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "nab-Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Halozyme Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 492,
      "start_date": "2016-03-14",
      "completion_date": "2019-11-04",
      "has_results": true,
      "last_update_posted_date": "2020-07-14",
      "last_synced_at": "2026-11-19T19:40:57.791Z",
      "location_count": 64,
      "location_summary": "Mobile, Alabama • Gilbert, Arizona • Fayetteville, Arkansas + 52 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02715804"
    },
    {
      "nct_id": "NCT00004933",
      "title": "Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "hydroxyurea",
          "type": "DRUG"
        },
        {
          "name": "Homoharringtonine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2000-01",
      "completion_date": "2001-05",
      "has_results": false,
      "last_update_posted_date": "2016-07-04",
      "last_synced_at": "2026-11-19T19:40:57.791Z",
      "location_count": 133,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 83 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004933"
    },
    {
      "nct_id": "NCT05395858",
      "title": "A Study to Learn More About Treatment With Damoctocog Alfa Pegol, How it is Used in Every Day Practice (\"Real-World\"), and How Satisfied People Who Receive Damoctocog Alfa Pegol Are in United States (US) Hemophilia Treatment Centers",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "No intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2023-01-17",
      "completion_date": "2023-11-06",
      "has_results": false,
      "last_update_posted_date": "2023-11-28",
      "last_synced_at": "2026-11-19T19:40:57.791Z",
      "location_count": 3,
      "location_summary": "Sacramento, California • New Orleans, Louisiana • Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05395858"
    },
    {
      "nct_id": "NCT01100658",
      "title": "Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "ALL, Childhood",
        "Leukemia, Lymphoblastic",
        "Leukemia, Lymphoblastic, Acute",
        "Leukemia, Lymphoblastic, Acute, L1",
        "Leukemia, Lymphoblastic, Acute, L2",
        "Leukemia, Lymphoblastic, Acute, Philadelphia-Positive",
        "Leukemia, Lymphocytic, Acute",
        "Leukemia, Lymphocytic, Acute, L1",
        "Leukemia, Lymphocytic, Acute, L2",
        "Lymphoblastic Leukemia",
        "Lymphoblastic Leukemia, Acute",
        "Lymphoblastic Leukemia, Acute, Childhood",
        "Lymphoblastic Leukemia, Acute, L1",
        "Lymphoblastic Leukemia, Acute, L2",
        "Lymphoblastic Lymphoma",
        "Lymphocytic Leukemia, Acute",
        "Lymphocytic Leukemia, L1",
        "Lymphocytic Leukemia, L2",
        "Brain Tumors",
        "Cancer of the Brain",
        "Cancer of Brain",
        "Malignant Primary Brain Tumors",
        "Brain Neoplasms, Malignant"
      ],
      "interventions": [
        {
          "name": "Methylphenidate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "8 Years to 17 Years"
      },
      "enrollment_count": 1,
      "start_date": "2010-05",
      "completion_date": "2010-11",
      "has_results": true,
      "last_update_posted_date": "2015-03-27",
      "last_synced_at": "2026-11-19T19:40:57.791Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01100658"
    },
    {
      "nct_id": "NCT00525148",
      "title": "LUX Lung 2 Phase II Single Arm BIBW 2992 \"Afatinib\" in NSCLC With EGFR Activating Mutations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "BIBW 2992",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 129,
      "start_date": "2007-08",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2016-09-16",
      "last_synced_at": "2026-11-19T19:40:57.791Z",
      "location_count": 23,
      "location_summary": "Bakersfield, California • Beverly Hills, California • Mission Hills, California + 19 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00525148"
    },
    {
      "nct_id": "NCT01606878",
      "title": "Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Childhood Solid Neoplasm",
        "Recurrent Childhood Anaplastic Large Cell Lymphoma",
        "Recurrent Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "Crizotinib",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Dexrazoxane Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Topotecan Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Vincristine Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "13 Months to 21 Years"
      },
      "enrollment_count": 46,
      "start_date": "2013-04-29",
      "completion_date": "2018-12-31",
      "has_results": true,
      "last_update_posted_date": "2024-01-05",
      "last_synced_at": "2026-11-19T19:40:57.791Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01606878"
    },
    {
      "nct_id": "NCT04740008",
      "title": "Impact of Low Nicotine Cigarette Messaging on Perceptions and Cigarette Choices",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Smoking",
        "Cigarette"
      ],
      "interventions": [
        {
          "name": "Low Nicotine Content Cigarettes",
          "type": "DRUG"
        },
        {
          "name": "Control message",
          "type": "OTHER"
        },
        {
          "name": "Test message",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2021-04-20",
      "completion_date": "2022-08-24",
      "has_results": false,
      "last_update_posted_date": "2024-02-26",
      "last_synced_at": "2026-11-19T19:40:57.791Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04740008"
    },
    {
      "nct_id": "NCT02566317",
      "title": "Stand & Move at Work",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obesity",
        "Hypertension",
        "Diabetes"
      ],
      "interventions": [
        {
          "name": "Sit-Stand workstation",
          "type": "DEVICE"
        },
        {
          "name": "Move",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "BEHAVIORAL"
      ],
      "sponsor": "Arizona State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 630,
      "start_date": "2016-01-15",
      "completion_date": "2018-12-15",
      "has_results": true,
      "last_update_posted_date": "2019-10-11",
      "last_synced_at": "2026-11-19T19:40:57.791Z",
      "location_count": 2,
      "location_summary": "Tempe, Arizona • Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02566317"
    },
    {
      "nct_id": "NCT05679401",
      "title": "A Study With Imlifidase in Anti-GBM Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anti-Glomerular Basement Membrane Disease",
        "Anti-Glomerular Basement Membrane Antibody Disease",
        "Goodpasture Syndrome",
        "Good Pasture Syndrome"
      ],
      "interventions": [
        {
          "name": "Imlifidase",
          "type": "DRUG"
        },
        {
          "name": "Plasma exchange (PLEX)",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide (CYC)",
          "type": "DRUG"
        },
        {
          "name": "Glucocorticoids",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Hansa Biopharma AB",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2022-12-22",
      "completion_date": "2026-02-02",
      "has_results": false,
      "last_update_posted_date": "2026-03-04",
      "last_synced_at": "2026-11-19T19:40:57.791Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05679401"
    },
    {
      "nct_id": "NCT04059536",
      "title": "Registry Study to Evaluate the Performance and Safety of Roxwood Medical Catheters in Arteries of Participants With a Stenotic Lesion or Chronic Total Occlusion (CTO)",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Total Occlusion",
        "Atherosclerosis",
        "Coronary Artery Disease",
        "Peripheral Artery Disease"
      ],
      "interventions": [
        {
          "name": "Roxwood Anchoring Catheters",
          "type": "DEVICE"
        },
        {
          "name": "Acetylsalicylic Acid",
          "type": "DRUG"
        },
        {
          "name": "Heparin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Boston Scientific Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "25 Years to 80 Years"
      },
      "enrollment_count": 0,
      "start_date": "2019-10-31",
      "completion_date": "2020-03-31",
      "has_results": false,
      "last_update_posted_date": "2021-07-21",
      "last_synced_at": "2026-11-19T19:40:57.791Z",
      "location_count": 11,
      "location_summary": "Phoenix, Arizona • Gainesville, Florida • Hobart, Indiana + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Hobart",
          "state": "Indiana"
        },
        {
          "city": "Hyattsville",
          "state": "Maryland"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04059536"
    }
  ]
}